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Imatinib, a multitargeted tyrosine kinase inhibitor, exhibits potent anticancer activity against leukemia
harboring the Bcr-Abl oncogene and some solid tumors overexpressing c-kit and PDGFR. However, its
clinical efﬁcacy is severely compromised by the emergence of resistance primarily due to acquired
mutations in the Bcr-Abl kinase domain. In this study, we showed that combination of imatinib with
platinum (Pt)-based anticancer agents, including cisplatin and oxaliplatin, exhibited synergistic cytotoxic
effect speciﬁcally in Bcr-Ablþ human chronic myeloid leukemia cell line K562 but not in Bcr-Abl
RPMI8226 cells. Importantly, the synergistic effect was also found to circumvent imatinib resistance in an
imatinib-selected resistant subline K562 ima1.0. The combination treatment increased apoptosis and
DNA damage. Mechanistic study revealed that increased inhibition of Bcr-Abl and downstream ERK
phosphorylation by the drug combination may contribute to the synergistic effect.
© 2015 Japanese Pharmacological Society. Production and hosting by Elsevier B.V. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Chronic myeloid leukemia (CML) is a myeloproliferative disor-
der resulting from the clonal expansion of a transformed multi-
potent hematopoietic stem cell. CML is characterized by the
Philadelphia chromosome (Ph) resulting from a balanced trans-
location between chromosome 9 and 22, which leads to the for-
mation of the Bcr-Abl fusion oncogene. The dysregulated Bcr-Abl
oncoprotein interacts with other cytoplasmic molecules and leads
to activation of downstream signaling pathways, RaseERK (extra-
cellular signal-regulated kinase), phosphatidylinositol 3-kinase
(PI3K)eAkt and signal transducer and activator of transcription 5
(STAT5), thereby driving cancer cell survival and proliferation (1).
Imatinib, approved by FDA in 2001, is an effective molecular tar-
geted drug for treating CML. Working as a competitive ATP inhib-
itor, imatinib speciﬁcally binds to the inactive conformation of Abl
(2), blocks all BcreAbl dependent phosphorylation and signaling
pathways, leading to cell apoptosis (3).ei), kennethto@cuhk.edu.hk
g).
rmacological Society.
. Production and hosting by ElseResistance to imatinib was evident not long after the introduc-
tion of the drug into clinical practice and it results in treatment
failure. A number of resistancemechanisms have been reported (4).
Combination of imatinib and multiple anticancer agents with
differingmechanisms of action has been investigated to circumvent
chemoresistance. While synergistic effect was observed in the
combination between imatinib and other standard CML anticancer
drugs (e.g. interferon-a and cytarabine), other drug combinations
were only additive or even antagonistic (5). The combinations of
imatinib with other molecularly targeted agents, including histone
deacetylase inhibitors, proteasome inhibitors, aminopeptidase in-
hibitors, TNF-a related apoptosis inducing ligands (5), and COX-2
inhibitor (celecoxib), have also been studied (6).
Platinum (Pt)-based anticancer drugs, exempliﬁed by cisplatin
and oxaliplatin, are the mainstay of treatment for solid tumors. Pt-
based drugs bind to N7 on purine nucleotides, and cause DNA
damage, subsequently resulting in cancer cell apoptosis (7). Com-
binations of imatinib with Pt-based drugs have been studied in
solid tumor cell lines. Synergistic cytotoxic effect has been reported
for combination of cisplatin and imatinib in head and neck cancer
(7) and metastatic nasophayngeal carcinoma (8). Combination of
carboplatin/paclitaxel and imatinib was also found to produce
synergistic effects in ovarian cancer cell lines (8). Imatinib can
potentiate the anticancer activity of cisplatin in lung cancer in vitro
(9), and the combination can synergistically inhibited the growth ofvier B.V. This is an open access article under the CC BY-NC-ND license (http://
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tinib was reported to alleviate cisplatin-induced nephrotoxicity in
rats, suggesting that imatinib may reduce the renal accumulation of
cisplatin (11). As for hematological cancers, it was reported that
imatinib could sensitize Bcr-Ablþ cells to cisplatin by simultaneous
inhibition of p53 transactivation and reduction of Bcl-xL (12). In
Bcr-Abl human leukemia cell line HL-60, imatinib and PRI-2191 (a
calcitriol analog) were found to enhance the cytotoxic effect of
cisplatin (13). The precise mechanism(s) contributing to the
enhanced anticancer effect in some of these studies is not well
deﬁned.
In this study, the combination effect of imatinib and Pt-based
anticancer drugs (cisplatin and oxaliplatin) was investigated in
Bcr-Abl positive (þ) (K562), negative () (RPMI8226) cells and in an
imatinib-selected resistant Bcr-Ablþ subline (K562 ima1.0). Com-
bination of imatinib with cisplatin/oxaliplatin was found to exhibit
synergistic cytotoxic effect in the Bcr-Ablþ but not in the Bcr-Abl
cells. Importantly, the synergistic effect was found to circumvent
imatinib resistance in the imatinib-selected resistant subline (K562
ima1.0). The combination treatment was found to increase
apoptosis and DNA damage. Mechanistic investigation revealed
that increased inhibition of Bcr-Abl and downstream ERK phos-
phorylation may contribute to the synergistic effect.
2. Materials and methods
2.1. Chemicals
Cisplatin and oxaliplatin were purchased from Acros Organics
(Thermo Fisher Scientiﬁc, New Jersey, USA). Imatinib and MTT (3-
(4, 5-Dimethylthiazol-2-yl)-2, 5-Diphenyltetrazolium Bromide)
was purchased from FARCO chemical supplies. All other chemicals
and solvents were of the best grade available.
2.2. Cell culture
Human leukemia cell lines K562 (Bcr-Ablþ CML) and RPMI 8226
(Bcr-Abl multiple myeloma plasma cell leukemia) were kind gifts
provided by Dr Susan Bates (National Cancer Institute, NIH, USA).
K562 was maintained in DMEM medium whereas RPMI8226 was
maintained in RPMI1640 medium supplemented with 10% fetal
bovine serum (Life Technologies, Grand Island, NY, USA), 100 units/
mL streptomycin sulfate (Life Technologies) and 100 units/mL
penicillin G sulfate (Life Technologies), and incubated at 37 C in 5%
CO2. An imatinib-resistant subline of K562 (K562 ima1.0) was
developed by exposing to increasing concentrations of imatinib,
starting with an initial concentration of 0.1 mM and gradually
increasing to 1 mM. At the time of experiments, K562 ima1.0 was
around 15-fold resistant to imatinib, relative to the parental
K562 cells.
2.3. Cytotoxicity of individual drugs and their combinations
The cytotoxicity of the drugs or their combinations were eval-
uated by the standard MTT assay (14). Cells were seeded in 96-well
microtitre plates at 7500 cells/well, and all drug treatments were
added immediately after cell seeding. The drugs were added
simultaneously for the combination study. The ratio of the two
drugs in combination was initially determined according to the
relative ratio of the IC50 values of initial drug alone. Cells were
treated with either individual drugs or their combinations for 72 h.
Combination index (CI) was used to evaluate the combination
effect based on IC50 values obtained from individual drugs alone
and combination treatment (15). CI was calculated according to the
following equation,CI ¼ (D)com1/(D)1 þ (D)com2/(D)2
inwhich (D)com1 (or (D)com2) is the IC50 value for drug1(or 2) in the
combination, (D)1 (or (D)2) is the IC50 value from individual drug
treatment. The resulting combination index (CI) was then used to
determine the outcome of the drug combination effect as (i) addi-
tive effect (CI¼ 1), (ii) synergism (CI< 1), or (iii) antagonism (CI> 1).
Dose-reduction index (DRI) was also calculated to indicate the
extent of dose reduction of individual drugs that can be facilitated
in a synergistic combination. DRI ¼ 1 indicates no dose reduction,
whereas DRI>1 and <1 indicate favorable and unfavorable dose-
reduction, respectively. The equation used here is DRI ¼ (D)1/(D)
com1, in which (D)com1 is the IC50 value for drug1 in the combi-
nation, (D)1 is the IC50 value from individual drug treatment (16).
Potential nephrotoxicity of drug combination was also deter-
mined by the MTT assay on LLC-PK1 porcine kidney epithelial cell
line. Conﬂuent LLC-PK1 cells in 96 wells plates (10,000 cells/well
seeded for one day) were treated by various drug combinations for
24 h. Percentage of surviving cells was then estimated by
comparing with the no treatment control.
2.4. Western blot analysis
Whole cell lysates prepared from K562 cells were separated by
SDS-PAGE and subjected to immunoblot analysis with the respec-
tive antibodies (phosphor-Bcr-Abl (Tyr-177) (Cell Signaling Tech-
nology, Danvers, MA, USA), PARP, phosphor-ERK1/2 (Thr177/
Thr160), ERK1/2, phosphor-histone H2Ax (Ser139) and GAPDH
(Santa Cruz Biotechnology, Santa Cruz, CA, USA)). The blot was
developed with WesternBright ECL Western blotting detection kit
(Advansta, Menlo Park, CA, USA) and analyzed with the FluorChem
Q Imaging System (Alpha Innotech, San Jose, CA, USA).
2.5. Apoptosis assay
K562 cells were treated for 48 h with 0.2 mM imatinib in the
presence or absence of cisplatin (10 mM). At the end of the treat-
ment, the cells were collected and washed twice with ice-cold PBS.
The extent of apoptosis was determined by using the APC Annexin
V apoptosis kit (BD Bioscience, San Jose, CA, USA) according to the
manufacturer's instructions. Cells positive for both Annexin V and
7-AAD were considered apoptotic. One-way analysis of variance
(one-way ANOVA) with Bonferroni's multiple comparison test was
used to compare the differences among various treatment groups.
A conﬁdence level of p < 0.05 was considered signiﬁcant.
2.6. Cellular Pt accumulation and DNA platination
Brieﬂy, K562 cells were incubated with 100 mM of the tested Pt
drugs at 37 C for 4 h. In pilot study, both drug accumulation and
DNA platinationwere found to be increased in a linear fashionwith
increasing drug concentration up to at least 400 mM. Afterward, the
cells werewashed twice with ice-cold PBS and then harvested in an
appropriate lysis buffer. For the determination of drug accumula-
tion, the cell lysates were resuspended in NETN buffer (100 mM
NaCl, 20 mM Tris HCl (pH 8.0), 0.5 mM EDTA, 0.5% NP-40), soni-
cated, and subjected to concentrated HNO3 digestion before anal-
ysis by Inductively Coupled Plasma Optical Emission Spectroscopy
(ICP-OES) (Perkin Elmer Optima 4300DV, UK). The absorbance of Pt
at 265.95 nmwas used for calculation. Protein concentration of the
lysate was measured separately by the Bradford method for
normalization purpose. For measurement of DNA platination, the
cell pellets were resuspended in Tris-Triton buffer (10 mM Tris,
100 mM NaCl, 1% Triton X-100) and subjected to proteinase K/
RNase inhibition before isolation of DNA by the standard phenol/
chloroform/isoamyl alcohol method. The DNA isolated was then
Y. Wei et al. / Journal of Pharmacological Sciences 129 (2015) 210e215212reconstituted in 100 mL TriseEDTA buffer before measurement of
DNA-bound Pt concentration by ICP-OES as described above. DNA
concentration of the samples was measured separately by UV
spectroscopy for normalization.3. Results
3.1. Combination of imatinib with Pt-based anticancer agents
shows synergistic cytotoxic effect in K562 cells expressing the Bcr-
Abl oncoprotein
3.1.1. Cell line models
Three leukemia cell line Bcr-Ablþ K562, its imatinib-selected
resistant subline (K562 ima1.0) and Bcr-Abl RPMI 8226 were
used in this study. K562 ima1.0 selected cell line was obtained by
incubating the parental K562 cells with increasing concentration of
imatinib (from 0.1 mMup to 1 mM) over a period of sixmonths. It has
been reported that resistance to imatinib can be induced by
different mechanisms, including acquisition of genemutations, Bcr-
Abl gene ampliﬁcation, overexpression of antiapoptotic proteins,
and increased drug efﬂux transporter P-glycoprotein (P-gp) (17).
We have brieﬂy characterized our imatinib-resistant K562 ima1.0
model. There was up-regulation of the phospho-Bcr-Abl protein in
our selected resistant K562 ima1.0 cell line (Fig.1A), suggesting Bcr-
Abl overexpression. While the mRNA of MDR1/P-gp was upregu-
lated 20 times in K562 ima1.0 than the parental K562 cells
(Supplementary Fig. 1), this efﬂux transporter upregulation may++-
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Fig. 1. Immunoblot analysis of inhibition of Bcr-Abl and ERK phosphorylation by
combination of imatinib and cisplatin in (A) K562 ima1.0 imatinib-resistant cells; and
(B) K562. The values under the image represent the mean densitometry-quantiﬁed
band intensity from three reproducible experiments. GAPDH serves as the loading
control for normalization.not play a major role in the observed imatinib resistance because
the use of a speciﬁc P-gp inhibitor (tariquidar) did not potentiate
the cytotoxic effect of imatinib in K562 ima1.0 (Supplementary
Table 1). On the other hand, sequencing of the Abl kinase domain
revealed no mutation.
3.1.2. Determination of individual IC50 values
IC50 values for K562 (Bcr-Ablþ), K562 ima1.0 (imatinib-resistant)
and RPMI 8226 (Bcr-Abl) cell lines after individual drug treatment
(imatinib, cisplatin or oxaliplatin) were determined (Table 1).
Combinations of imatinibwith cisplatin or oxaliplatin at ﬁxed ratios
of their IC50 were then evaluated.
3.1.3. Synergistic cytotoxic effect of imatinib-Pt drug combinations
was only achieved in K562 (Bcr-Ablþ) cells
Combinations of imatinib with cisplatin or oxaliplatin were
evaluated in K562 (Bcr-Ablþ), K562 ima1.0 (imatinib-resistant) and
RPMI8226 (Bcr-Abl) cells. First, equipotent dose ratio of imatinib
and cisplatin (or oxaliplatin) was used in the combination treat-
ment. The concentrations were chosen so that each drug in the
combination contributed equally to the overall cytotoxic effect.
Then, other ﬁxed ratios of the two drugs were also evaluated to ﬁnd
out if the combination effect is universal. Combination effect was
evaluated by calculating the combination index (CI) and dose-
reduction index (DRI).
In K562 (Bcr-Ablþ), all combinations of imatinibwith cisplatin (or
oxaliplatin) gave rise to CI values signiﬁcantly below 1 at fa (frac-
tional growth inhibition) ¼ 0.5, indicating synergistic effect. In
contrast, in RPMI 8226 (Bcr-Abl), combinations of imatinib with Pt
drugs only produced CI values of approximately 1, suggesting addi-
tive effect (Table 2). K562 ima1.0, which is an imatinib-selected
resistant subline, showed resistance towards imatinib treatment.
Compared with parental K562 cell line, IC50 value increased more
than 10 times in the K562 ima1.0 cells (Table 1). Importantly, syn-
ergistic effect from cisplatin/oxaliplatin and imatinib combination
was also evident in the imatinib-resistant K562ima1.0 cells (Table 2).
The DRI was also calculated to reveal if dose reduction is
attainable in the drug combination. Consistent with the result in CI,
drug combinations in Bcr-Ablþ K562 cells made the DRI value
remarkably greater than 1 (Supplementary Table 2).
3.1.4. Combination of Pt-based agents and imatinib did not increase
nephrotoxicity
Nephrotoxicity represent a notorious toxicity of the classical Pt
drug cisplatin. MTT assay was used to evaluate whether the drug
combination between cisplatin and imatinib could affect the po-
tential nephrotoxic effect. LLC-PK1 cells are widely used in vitro
model for the investigation of nephrotoxic potential of drugs. When
grown to conﬂuent, they represent the physiologic features of the
kidney epithelial cells in the body. As shown in Fig. 2, cisplatin was
found to exhibit a concentration-dependent toxic effect in LLC-PK1
cells whereas imatinib did not signiﬁcantly affect the cell viability.
Importantly, combination of imatinib with cisplatin did not further
increase the toxicity compared with cisplatin treatment alone.Table 1
IC50 value of compounds on each cell line.
IC50
(mM)
K562
(Bcr-Abl)
K562 ima1.0
(Resistent)
RR RPMI 8226
(non Bcr-Abl)
Imatinib 0.15 ± 0.02 2.08 ± 0.48 14 11.83 ± 0.91
Cisplatin 19.76 ± 1.42 17.47 ± 1.06 0.88 2.97 ± 0.82
Oxaliplatin 16.55 ± 2.08 16.43 ± 1.14 0.99 0.43 ± 0.04
RR (resistance ratio) was obtained by IC50 value of resistant cell line K562 ima1.0
divided by IC50 of parental K562.
Table 2
Combination index (CI) of each combination at fa ¼ 0.5.
Cell line Combination index Pt_I 20:1 Pt_I 80:1 Pt_I 200:1
K562 CI (cisplatin-imatinib) 0.57 ± 0.09 0.33 ± 0.09 0.48 ± 0.10
(Bcr-Ablþ) CI (oxalipaltin-imatinib) 0.62 ± 0.05 0.35 ± 0.03 0.38 ± 0.07
Cell line Combination index Pt_I 1:10 Pt_I 10:1 Pt_I 100:1
K562 ima1.0 CI (cisplatin-imatinib) 0.46 ± 0.08 0.48 ± 0.11 0.51 ± 0.10
(Resistant Bcr-Ablþ) CI (oxalipaltin-imatinib) 0.55 ± 0.07 0.38 ± 0.10 0.52 ± 0.06
Cell line Combination index Pt_I 1:10 Pt_I 1:50 Pt_I 5:1
RPMI 8226 CI (cisplatin-imatinib) 1.30 ± 0.24 0.98 ± 0.31 1.14 ± 0.09
(Bcr-Abl-) CI (oxalipaltin-imatinib) 1.41 ± 0.41 0.84 ± 0.12 0.90 ± 0.08
PteI: means “Pt-based compound: imatinib”. Following ratios are the combination ratio of two components.
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positive) cells
Data from immunoblot analysis demonstrated that imatinib
induced apoptosis in a concentration-dependent manner in Bcr-Abl
positive K562 cells (Fig. 3A). 0.2 mM imatinib and 20 mM cisplatin
(individually only induced a low degree of apoptosis) were chosen
for the combination study. The drug combination was found to
increase higher level of cleaved PARP (20%), compared with indi-
vidual cisplatin (4%) and imatinib (9%) (Fig. 3B), indicating
increased apoptosis. This is consistent with the data obtained from
the Annexin V-7AAD apoptosis assay where combination of
cisplatin and imatinib produced more apoptotic cells (Fig. 4).
3.3. Combinations of cisplatin and imatinib increased inhibition of
Bcr-Abl and ERK phosphorylation
K562 cells are endowed with constitutively active Abl kinase
activity because of the Bcr-Abl fusion oncoprotein. This activated
Bcreabl tyrosine kinase could lead to activation of its downstream
signaling pathways, including the Rasemitogen-activated protein
kinase (MAPK), the Janus-activated kinase (JAK)eSTAT pathway,
and the phosphoinositide 3-kinase (PI3K)/AKT pathway (1),
thereby driving cancer growth.
While imatinib works by speciﬁcally blocking Bcreabl auto-
phosphorylation and its downstream signaling pathways,
cisplatin is devoid of this effect. Interestingly, the combination of
imatinib with cisplatin was found to exhibit greater inhibition of
Bcr-Abl and downstream ERK phosphorylation both on Bcr-Ablþ
K562 and the selected resistance subline K562 ima1.0 (Fig. 1A,B),
compared with imatinib treatment alone.100.0 
76.7 
91.0 
82.4 
60.1 
73.1 
58.5 
44.4 
70.0 
39.6 
0.0
20.0
40.0
60.0
80.0
100.0
su
rv
iv
in
g 
ce
ll 
(%
)
Cisplatin
Imatinib
-
-
50
-
-
0.625
50
0.625
100
-
-
1.25
100
1.25
200
-
-
2.5
200
2.5 (μM)
P=0.105
P=0.371 P=0.092
Fig. 2. Toxicity of combinations of imatinib and cisplatin in normal porcine kidney cell
line LLC-PK1. Cisplatin exhibited a concentration dependent toxic effect while imatinib
did not signiﬁcantly affect the cell viability. Combination of imatinib with cisplatin at
different ratios (cisplatin:imatinib ¼ 100:1, 80:1) did not further increase the toxicity
(p > 0.05).3.4. Combinations of cisplatin and imatinib increased DNA damage
in Bcr-Ablþ K562
3.4.1. Immunoblot analysis of DNA damage
Classical Pt-based compounds are known to induce DNA
damage. The combination of cisplatin and imatinib was found to
speciﬁcally increase the expression of the DNA damage marker
phospho-gH2Ax in the Bcr-Ablþ K562 but not in the Bcr-Abl RPMI
8226 cells (Fig. 5A). Immunoﬂuorescence imaging of phospho-
gH2AX labeled cells also conﬁrmed that the drug combination
gave rise to more punctate g-H2Ax foci in the nucleus (Fig. 5B),
consistent with more DNA damage relative to the individual drugs
alone.
3.4.2. Platinum accumulation
The increased DNA damage in the drug combination may be
mediated by a change in the drug accumulation of the Pt drug. Total
Pt accumulation was therefore measured in K562 cells after incu-
bation with cisplatin/oxaliplatin alone (100 mM) or their combina-
tion with 1.25 mM/5 mM imatinib. The equipotent concentration
ratio (Pt drug: Imatinib ¼ 80:1) or more of imatinib (20:1) in the
drug combination was chosen for our experiments. No statistical
difference was observed in the Pt accumulation between the Pt
drug alone and the combination treatment (Supplementary
Table 3).
Pt drugs are known to be actively pumped out by efﬂux trans-
porters including ATP7A and MRP2 (18). The efﬂux of cisplatin in
K562 cells was also monitored for 0, 2, or 4 h after a 4-h drug in-
cubation with cisplatin alone (100 mM) or its combination with
1.25 mM imatinib. As expected, there was less Pt drug accumulation
in the cells over time in drug-free medium because they are being
actively pumped out. However, there was no statistical signiﬁcant
difference in drug efﬂux in the cisplatin alone and drug combina-
tion treatment (Table 3).full length
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Fig. 3. Immunoblot analysis showing the apoptotic effect of imatinib and its combi-
nation with cisplatin. (A) Concentration dependent effect of imatinib; (B) combination
of imatinib (0.2 mM) with cisplatin (20 mM).
Table 3
Platinum accumulation and efﬂux (ng Pt/mg protein).
Time/sample Pt accumulation Time/sample Pt accumulation
0 h Cisplatin 27.85 ± 1.11 0 h Cisplatin:imatinib 80:1 23.96 ± 2.41
2 h Cispaltin 15.8 ± 2.11 2 h Cisplatin:imatinib 80:1 17.53 ± 1.97
4 h Cisplatin 14.0 ± 1.74 4 h Cisplatin:imatinib 80:1 16.00 ± 1.64
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The extent of DNA platination was also evaluated after incuba-
tion of K562 cells in cisplatin/oxaliplatin alone (100 mM) or their
combinationwith 1.25/5 mM imatinib for 4 h. The data showed that
there is no statistical signiﬁcant difference in DNA platination++-
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Fig. 5. (A) Immunoblot analysis showing the enhanced DNA damage by imati-
nibecisplatin combination in Bcr-Ablþ K562 cells, but not Bcr-Abl- RMPI8226 cells. The
values under the image represent the mean densitometry-quantiﬁed band intensity
from three reproducible experiments. GAPDH serves as the loading control for
normalization. (B) Immunoﬂuorescence imaging of phospho-gH2Ax labeled K562 cells
(Bcr-Ablþ) after 24-h treatment with the indicated drugs or drug combination. More
punctate gH2Ax foci were observed in the drug combination versus the two individual
drugs alone.between the Pt drug alone and the combination treatment
(Supplementary Table 4).4. Discussion
Combination of imatinibwith other anticancer agents have been
investigated to circumvent drug resistance and to improve thera-
peutic response in CML treatment. In this study, drug cytotoxicity
data demonstrated a synergistic cytotoxic effect between the Bcr-
Abl-targeting imatinib and classical cytotoxic Pt-based anticancer
drugs (cisplatin and oxaliplatin) speciﬁcally in K562 (Bcr-Ablþ)
human leukemia cell line and its imatinib-selected resistant subline
K562 ima1.0 (Table 2). Besides improving the therapeutic response
in leukemia cells, the imatinib and Pt-drug combination may help
circumvent imatinib resistance. The drug combination is also likely
to be safe because toxicity in the combination groups produce the
same extent of cytotoxic effect as cisplatin alone in a normal
porcine kidney epithelial cell line LLC-PK1 (Fig. 2). In this study, we
only applied the combination treatments on Bcr-Abl RPMI8226,
Bcr-Ablþ K562 and its imatinib-selected resistant subline K562
ima1.0. For further investigation, other CML cell lines, especially
those expressing resistance-causing mutant Bcr-Abl are needed.
Moreover, examination of the combination effect of imatinib with
other approved chemotherapeutic agents for CML on the above
study models would provide more comprehensive references to
evaluate the synergistic effect from combination of imatinib and Pt-
based drugs.
Since the synergism effect was speciﬁcally observed only in Bcr-
Ablþ K562 cells, Bcr-Abl and its downstream signaling molecules
may play a key role in the observation. Western blot analysis
showed more inhibition of Bcr-Abl (about 45%) and ERK (28%)
phosphorylation by the drug combination treatment, than the in-
dividual imatinib alone (Bcr-Abl (about 21%) and ERK (8%)) in K562
sensitive cells (Fig. 1B).
Since more prominent DNA damage (indicated by the DNA
damage marker phospho-gH2Ax) was induced by the drug com-
bination only in Bcr-Ablþ cell lines, cellular platinum accumulation
and DNA platination were then studied. Our data indicated that
imatinib had no effect on Pt-drugs accumulation and efﬂux.
Consistently, the extent of DNA platination was also similar in the
Pt-drug alone and the drug combination group. These results
indicated combination with imatinib, Pt-drugs did not form addi-
tional Pt-DNA adducts. We speculate that the increased DNA
damage may be contributed by the enhanced Bcr-Abl inhibition in
the drug combination (Fig. 5). It has been reported that imatinib
sensitized Bcr-Ablþ cells to cisplatin by simultaneous inhibition of
p53 transactivation, induction of p53 accumulation predominantly
in the cytoplasm, and reduction of Bcl-xL (12). These ﬁndings were
obtained in BaF3 cells harboring wild type p53 and Bcr-Abl. How-
ever, it cannot completely explain the observation in K562 because
K562 cells do not express functional p53 (19). In our study,
compared with the individual Pt drug or imatinib, the drug com-
bination did not further induce the p53-dependent proapoptotic
genes BAX and PUMA (Supplementary Fig. 2). Thus, the observed
synergistic effect may not be mediated by a p53-mediated mech-
anism. Interestingly, the anti-apoptotic gene Bcl2 was
Y. Wei et al. / Journal of Pharmacological Sciences 129 (2015) 210e215 215downregulated by the drug combination versus imatinib treatment
alone (Supplementary Fig. 2), which may contribute to the
observed synergistic effect. Further mechanistic study, by which
imatinib potentiated antitumor effect of cisplatin and vice versa, is
needed to fully elucidate the speciﬁcity of our observed Bcr-Abl-
speciﬁc synergistic combination cytotoxicity of imatinib with
classical Pt-based anticancer drugs.
Our study demonstrated a Bcr-Abl-speciﬁc synergistic cytotoxic
effect from combinations of imatinib and Pt-based anticancer
drugs. The synergistic effect may be exploited to help circumvent
imatinib resistance. More extensive inhibition of Bcr-Abl and its
downstream ERK pathway may contribute to the synergistic effect.
The results warrant further study to develop the drug combination
to improve therapeutic efﬁcacy in the treatment of CML.
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